pharma · Asthma · Type 2 Diabetes
AstraZeneca
AstraZeneca is a pharma organization headquartered in Södertälje, SE. Primary therapeutic focus areas include Asthma, Type 2 Diabetes, Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Pulmonary Disease,
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 129
- Drugs
- 77
- Patents
- 25
MEDI4736
Phase 2 · small molecule · Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
MEDI4736 for Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck is a Phase 2 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Internal code D4193C00001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AstraZeneca
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
- Status
- completed
- Trials
- 1